
Opinion|Videos|May 19, 2025
Treatment or Lack of Treatment of Small Renal Masses
Explore treatment options for small renal masses, including surveillance, surgery, and biopsy, while understanding the role of ccRCC PET in diagnosis.
Advertisement
Episodes in this series

Treatment Approaches and Role of Biopsy
Main Discussion Topics:
- Masses under 2 cm are typically managed with active surveillance.
- Options for masses that are 2 to 4 cm include ablation (eg, cryotherapy, radiofrequency ablation) and surgical approaches.
- Kidney cancer is often treated without tissue diagnosis, unlike most other cancers.
- Biopsy utilization depends on tumor characteristics and management implications.
Key Points for Physicians:
- Small masses (< 2cm) are generally appropriate for active surveillance.
- Approximately 60% to 70% of small renal masses are malignant.
- Biopsy is considered for unusual lesions, suspected metastases, or infiltrative patterns.
- Risk stratification can be enhanced by considering patient age, gender, and tumor size.
Notable Insights:
Kidney cancer remains one of the few cancers typically treated without tissue confirmation, though this approach is increasingly being questioned.
Clinical Significance:
Size-based management algorithms provide practical guidance, but patient-specific factors and tumor characteristics should inform individualized treatment decisions.
Advertisement
Related to this article

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.

Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.

Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Advertisement
Advertisement
Trending on Urology Times
1
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
2
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
3
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
4
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
5

